



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Role of Antificolin II Antibody in Lupus Nephritis

Thesis

Submitted for Partial Fulfillment of Master
Degree in **Internal Medicine**

By

Ibrahim Sami Ibrahim

M.B.B.Ch, M.SC

Cairo University

Supervised by

Prof. Dr. Mohamed Nazmy Farres

*Professor of Internal Medicine and Clinical Immunology
Faculty of Medicine, Ain Shams University*

Dr. Sylvia Talaat Kamal

*Lecturer of Internal Medicine and Clinical Immunology, Faculty
of Medicine, Ain Shams University*

Dr. Fatma Abdelrahman Ahmed

*Lecturer of Internal Medicine and Nephrology
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my deepest gratitude and thanks to my beloved wife **A&M&A**, dear mother and my kids.. You were my backbone in every step and every single day.*

*I'd like to express my respectful thanks and profound gratitude to **Prof./ Mohamed Nazmy Farris**, Professor of Internal Medicine and Clinical Immunology, Faculty of Medicine, Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I would like to express my hearty thanks to **Dr./ Sylvia Talaat Kamal** Lecturer of Internal Medicine and Clinical Immunology, Faculty of Medicine, Ain Shams University for her kind care, continuous supervision, valuable instructions, constant help, great assistance and support till this work was completed.*

*I would like to express my hearty thanks to **Dr./ Fatma Abdelrahman Ahmed** Lecturer of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University for her support till this work was completed*

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Obrahim Sami Obrahim Abdulaziz Sehsah

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	iii
List of Abbreviations	v
Introduction.....	1
Aim of the Work.....	4
Review of Literature	
Lupus nephritis	5
Diagnosis and management of lupus nephritis	27
Antificolin II antibody	64
Patients and Methods.....	80
Results.....	91
Discussion.....	112
Summary.....	119
Conclusion	121
Recommendations.....	122
References.....	123
Arabic Summary	---

List of Tables

Table No.	Title	Page No.
Table (1):	International Society of Nephrology/Renal Pathology Society 2003 classification of LN.....	22
Table (2):	Urine biomarkers that correlate with lupus nephritis activity in cross-sectional studies	37
Table (3):	Serum biomarkers that correlate with lupus nephritis activity in cross-sectional studies	47
Table (4):	Summary of biomarkers reviewed.....	52
Table (5):	The reported sensitivity and specificity of some potential serum and urine biomarkers in lupus nephritis	53
Table (6):	Renal response criteria in global systemic lupus erythematosus scoring tools.....	55
Table (7):	National Institutes of Health Activity and Chronicity Indices.....	58
Table (8):	Commonly Used Regimens for Induction of Remission in Proliferative Lupus Nephritis	60
Table (9):	Demographic data of the three study groups:	91
Table (10):	Demographic data according to SLE activity	91
Table (11):	Clinical characteristics of patients with SLE.....	92
Table (12):	Medical data and duration of disease among SLE patients with and without renal affection.....	92
Table (13):	Histopathological classification of renal biopsy among SLE patients with LN	93
Table (14):	Laboratory investigations of the three study groups.....	94
Table (15):	Treatment lines of SLE patients with and without renal affection	95
Table (16):	Antificolin-2 antibody titer between SLE patients and comparable controls	96

List of Tables (cont...)

Table No.	Title	Page No.
Table (17):	Antificolin-2 antibody titer between the three study groups	96
Table (18):	Pairwise comparison of Kruskal Wallis test.....	97
Table (19):	Antificolin-2 antibody titer between active and inactive SLE patients	98
Table (20):	Relation between Antificolin-2 antibody and renal biopsy results among SLE patients with LN	103
Table (21):	Comparison between Antificolin-2 antibody and Anti-ds DNA among SLE patients with LN.....	105
Table (22):	Correlation between Antificolin-2 antibody and some parameters within SLE patients with LN group	106
Table (23):	Comparison between Antificolin-2 antibody and clinical manifestations among active SLE patients	108
Table (24):	Multiple linear regression analysis for factors affecting Antificolin-2 antibody level among active SLE patients.....	109
Table (25):	Multiple linear regression analysis for factors affecting Antificolin-2 antibody level among SLE patients.....	110
Table (26):	Multiple linear regression analysis for factors affecting Antificolin-2 antibody level among SLE patients with LN	111

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Pathogenesis of LN.....	9
Figure (2):	Pathogenesis of lupus nephritis	10
Figure (3):	The class 1 light microscopy with hematoxylin and eosin staining is essentially normal	16
Figure (4):	Class 3 LN light microscopy shows segmental endocapillary proliferation, electron microscopy shows subendothelial electron-dense immune deposits, and immunofluorescence microscopy shows IgG along the glomerular capillary walls	18
Figure (5):	The class 5 biopsy was stained with silver instead of hematoxylin and eosin to better illustrate the glomerular basement membrane material (black).	19
Figure (6):	Urine sediment findings in lupus nephritis. Acanthocytes are dysmorphic red blood cells that indicate glomerular bleeding	30
Figure (7):	Algorithm for the management of class 5 lupus nephritis	61
Figure (8):	L-ficolin structure. The glycosylated gene product of Mr 35 K forms a basic triplet subunit	68
Figure (9):	The human <i>FCN2</i> gene.....	70
Figure (10):	General view of complement activation.....	73
Figure (11):	Antificolin-2 antibody titer between the three study groups.....	97
Figure (12):	Validity of Antificolin-2 antibody for differentiation between SLE patients and healthy controls	99
Figure (13):	Validity of Antificolin-2 antibody for differentiation between proliferative and non-proliferative groups	100

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (14):	Validity of Antificolin-2 antibody for differentiation between SLE patients with LN and SLE patients without LN	101
Figure (15):	Validity of Antificolin-2 antibody for differentiation between active and inactive patients	102
Figure (16):	Antificolin-2 antibody level in proliferative and non-proliferative lupus nephritis	104
Figure (17):	Antificolin-2 antibody level in different renal biopsy classes	104
Figure (18):	Comparison between Antificolin-2 antibody and Anti-ds DNA among SLE patients with LN.....	105
Figure (19):	Correlation between Antificolin-2 antibody and SLEDAI score among SLE patients with renal affection.....	107

List of Abbreviations

Abb.	Full term
<i>ACEi</i>	<i>Angiotensin-converting enzyme inhibitor</i>
<i>ACR</i>	<i>According to American College of Rheumatology</i>
<i>AI</i>	<i>Activity index</i>
<i>ANA</i>	<i>Antinuclear antibodies</i>
<i>Anti- NCS</i>	<i>Anti-nucleosome</i>
<i>APO</i>	<i>Apolipoprotein</i>
<i>APOL1</i>	<i>Apolipoprotein risk variants</i>
<i>ARB</i>	<i>Angiotensin receptor blocker</i>
<i>BAFF</i>	<i>B-cell activating factor</i>
<i>BLC</i>	<i>Blymphocyte chemoattractant</i>
<i>BLyS</i>	<i>B-lymphocyte stimulator protein</i>
<i>CCL2</i>	<i>Urinary MCP-1</i>
<i>CI</i>	<i>Chronicity index</i>
<i>CKD</i>	<i>Chronic kidney disease</i>
<i>CL-K1</i>	<i>Collectin-11</i>
<i>CRHD</i>	<i>Chronic rheumatic heart disease</i>
<i>CXCL16</i>	<i>Chemokine ligand 16</i>
<i>ESI</i>	<i>Electrospray ionization</i>
<i>ESRD</i>	<i>End-stage renal disease</i>
<i>FcgR</i>	<i>Fc receptors for IgG</i>
<i>FCN2</i>	<i>L-ficolin gene</i>
<i>FDs</i>	<i>Fibrinogen-like domains</i>
<i>GBM</i>	<i>Glomerular basement membrane</i>
<i>GFR</i>	<i>Glomerular filtration rate</i>
<i>ICAM</i>	<i>Intracellular adhesion molecule</i>
<i>ICAM-1</i>	<i>Intracellular adhesion molecule-1</i>
<i>IFN- α</i>	<i>Interferon- α</i>
<i>ISN</i>	<i>International Society of Nephrology</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>Kim-1</i>	<i>Kidney injury molecule-1</i>
<i>L-ficolin</i>	<i>Ficolin-2</i>
<i>LN</i>	<i>Lupus nephritis</i>
<i>MAGE-B2</i>	<i>Melanoma associated antigen gene B2</i>
<i>MASP's</i>	<i>MBL / Ficolin associated serine proteases</i>
<i>MBL</i>	<i>Mannose-binding lectin</i>
<i>MCP-1</i>	<i>Monocyte chemoattractant protein-1</i>
<i>MDRD</i>	<i>Modification of Diet in Renal Disease</i>
<i>M-ficolin</i>	<i>Ficolin-1</i>
<i>MIG</i>	<i>Monokine induced by IFN-γ</i>
<i>miRNAs</i>	<i>MicroRNAs</i>
<i>MS</i>	<i>Mass spectrometry</i>
<i>NETS</i>	<i>Neutrophil extracellular traps</i>
<i>OPG</i>	<i>Osteoprotegerin</i>
<i>pDCs</i>	<i>Plasmacytoid dendritic cells</i>
<i>pSLE</i>	<i>Pediatric SLE</i>
<i>PTX3</i>	<i>Pentraxin 3</i>
<i>Q</i>	<i>Quadrupole</i>
<i>RAAS</i>	<i>Renin-angiotensin-aldosterone system</i>
<i>ROC</i>	<i>Receiver operating characteristic curve</i>
<i>RPS</i>	<i>Renal Pathology Society</i>
<i>SLE</i>	<i>Systemic lupus erythematosus</i>
<i>TOF</i>	<i>Time of flight tandem</i>

INTRODUCTION

Systemic Lupus Erythematosus

SLE is a chronic autoimmune disease that can affect virtually any organ of the body in which different immunological occasions can prompt a comparative clinical picture, described by a wide scope of clinical manifestations and target organs with erratic flares and abatements that in the long run lead to permanent injury.

SLE can affect several organs and systems, including the joints, skin, brain, heart, lungs, blood vessels, and kidneys. (*Colliard et al., 2018*).

It can be diagnosed based on a combination of clinical findings and laboratory work. According to American College of Rheumatology (ACR) presence of 4 out of the 11 clinical criteria for diagnosis of SLE yields a sensitivity and specificity of 85% and 95% respectively.

Auto antibodies circulating the body directed against self-antigen as ds DNA, nuclear antigen and several cytoplasmic components feature main histopathology of SLE (*Ortega et al., 2010*).

Lupus nephritis

It is one of the most serious complications of SLE

affecting almost 66-90% of lupus patients with variable incidence and prevalence depending on studied population. It is higher in Asian and Africans than Caucasians 55%, 51% and 14% respectively.

LN develops early in the course of lupus activity leading to development of end-stage renal disease (ESRD) after 10 years of renal affection in up to 25% of patients; however, it may appear after several years in 5% of patients known as delayed lupus nephritis.

Auto antibodies and immune complexes with subsequent infiltration by inflammatory cells in renal tissue is the most likely pathogenesis of LN (*Nisihara et al., 2013*).

Complement system

As part of innate immunity, complement system plays a dual role in pathogenesis of SLE. Genetic deficiency of complement factors is associated with the occurrence of SLE, however, massive complement activation during lupus activity is a major contributor to lupus inflammatory reactions.

There are three distinct pathways for complement system activation.

Binding of the pattern recognition molecule C1q to antibody-antigen complexes initiate classical pathway.

Slow, spontaneous hydrolysis of the central complement